Ikarian Capital’s Ocular Therapeutix OCUL Stock Holding History

Ikarian Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,590	Closed	-$67.8K	–	163
2023 Q3	$67.8K	Sell	21,590 -78,410	-78%	-$321K	0.01%	128
2023 Q2	$516K	Sell	100,000 -100,000	-50%	-$595K	0.08%	99
2023 Q1	$1.05M	Hold	200,000	–	–	0.24%	75
2022 Q4	$562K	Sell	200,000 -65,000	-25%	-$215K	0.14%	54
2022 Q3	$1.1M	Buy	+265,000	New	+$1.33M	0.22%	68
2022 Q2	–	Sell	-29,644	Closed	-$147K	–	184
2022 Q1	$147K	Buy	29,644 +2,093	+8%	+$11.6K	0.02%	172
2021 Q4	$191K	Sell	27,551 -250,000	-90%	-$1.94M	0.03%	160
2021 Q3	$2.77M	Sell	277,551 -142,022	-34%	-$1.6M	0.2%	112
2021 Q2	$5.95M	Hold	419,573	–	–	0.48%	58
2021 Q1	$6.88M	Sell	419,573 -265,000	-39%	-$5.1M	0.23%	96
2020 Q4	$14.2M	Sell	684,573 -1,031,720	-60%	-$15.3M	0.62%	38
2020 Q3	$13.1M	Sell	1,716,293 -339,684	-17%	-$2.82M	0.95%	26
2020 Q2	$17.1M	Buy	2,055,977 +497,041	+32%	+$3.29M	1.36%	17
2020 Q1	$7.72M	Buy	1,558,936 +1,001,277	+180%	+$4.94M	0.58%	43
2019 Q4	$2.2M	Buy	+557,659	New	+$1.94M	0.36%	61

Other funds holding OCUL

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Ikarian Capital's OCUL Position: Q4 2023 in Review

Ikarian Capital sold out of Ocular Therapeutix (OCUL) in Q4 2023, closing a stake of 21,590 shares — an estimated $67.8K sold.

Ikarian Capital first reported a position in OCUL in Q4 2019 and held it in 15 quarters. The position peaked at $17.1M in Q2 2020. 118 funds tracked by Wall St. Rank hold OCUL as of Q4 2023.

Ikarian Capital reported no remaining Ocular Therapeutix position as of Q4 2023 after selling out during the quarter.
Ikarian Capital sold 21,590 Ocular Therapeutix shares in Q4 2023, an estimated $67.8K.
Ikarian Capital first reported a position in Ocular Therapeutix in Q4 2019 and held it in 15 quarters.
Ikarian Capital's Ocular Therapeutix position peaked at $17.1M in Q2 2020.
118 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2023.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.